Head-to-head · Value Score
Vitara RX vs Contour Health
Two GLP-1 deals, scored on the same six factors. Vitara RX lands a Value Score of 91, Contour Health a 72. Here's who gives you the honest lower price — and where each one bites back.
Vitara RX
#4 · Grade A · Best Value
Est. first month
$99/mo
Save ~93% vs brand-nameContour Health
#191 · Grade C · Watch List
Est. first month
From $160/mo (starting dose, compounded)
Save ~88% vs brand-nameThe verdict
Vitara RX takes it on Value Score, 91 to 72 — an est. $99/mo first month, with no teaser step-up baked in. Contour Health isn't out of it: Shoppers who want pay-per-vial compounded semaglutide or tirzepatide with no long-term subscription commitment.
Deal-by-deal
The numbers that decide it. Green ✓ marks the stronger side on each line.
| Deal | Vitara RX | Contour Health |
|---|---|---|
| Value Score | 91 (A) | 72 (C) |
| Est. first month | $99/mo | From $160/mo (starting dose, compounded) |
| Save vs brand-name | ~93% | ~88% |
| Semaglutide | $99/mo | From $160/mo (starting dose, compounded) |
| Tirzepatide | $149/mo | From $300/mo (starting dose, compounded) |
| Both molecules | Yes | Yes |
| Pricing | Flat — no step-up | Watch |
| Coverage | 49 states | Coverage not published |
Factor by factor
The six factors behind each Value Score. The orange bar marks the stronger side. See the methodology.
Vitara RX
VitaraRx is a direct-to-consumer telehealth marketplace offering compounded semaglutide and tirzepatide at flat per-drug pricing across all doses — no membership or hidden fees.
Why it's a deal
- Among the lowest flat pricing in the market — $99/mo semaglutide and $149/mo tirzepatide, all doses same price
- Names its 503A pharmacy partner (Manifest Pharmacy, Greer SC) — strong supply-chain transparency
- LegitScript Certified
- Publishes the FDA compounded-medication disclaimer
- Covers 49 states with an explicit state list, not vague "most states" language
The fine print
- No corporate legal entity disclosed — only the trade name "VitaraRx"
- No named medical director — all clinical decisions made by independent providers (marketplace model)
- All sales final — no medication returns
- Per-vial mg quantity isn't clearly disclosed, making price comparisons harder
- Doesn't ship to Alaska
Contour Health
Contour Health (Desert Contour LLC) is a Utah-based telehealth provider offering compounded semaglutide and tirzepatide through a named 503A pharmacy partner, Strive Pharmacy.
Why it's a deal
- Free medical consultation — no charge to talk with a provider before starting
- Pay-per-vial pricing with no long-term subscription commitment required to participate
- Names its compounding pharmacy partner (Strive Pharmacy, 503A accredited) — a real transparency signal
- LegitScript badge links to a genuine, working LegitScript verification checker for the domain
- Board-certified Medical Director and named nurse-practitioner care team, not anonymous providers
The fine print
- State availability list is not published — Terms of Service only says "certain states"
- All product purchases are non-refundable per Terms of Service
- Compounded injectable only — no oral option, no brand-name Wegovy/Zepbound/Ozempic/Mounjaro
- Terms of Service also describe an optional subscription tier with a 3-month minimum, despite marketing emphasizing "no subscriptions"
- No insurance, Medicare, or Medicaid accepted — cash-pay or HSA/FSA only
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes a Value Score.
Neither one the right fit? Every program that outscores Vitara RX is ranked on the Vitara RX alternatives board, and the same list for the other side is on alternatives to Contour Health.
More head-to-heads
Prices, states and verification reflect each program's public disclosures at last check; the Value Score is our editorial judgment per the methodology. “Save vs brand-name” compares the lowest disclosed monthly price against a ~$1,349/mo brand-name cash reference. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.